Replimune submits RP1/Opdivo BLA for melanoma
Replimune Group filed a Biologics License Application for RP1 combined with nivolumab to treat advanced cutaneous melanoma following anti-PD-1 failure. The filing relies on a single-arm pivotal trial and comes amid key alignments and accumulating clinical data.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day